Skip to content

Rafael Holdings, Inc. RFL Other Research And Development Expense

Other Research And Development Expense at other companies

OS Therapies logo
OS TherapiesOSTX
$0
CTO
Citius Oncology, Inc.CTOR
$469K-2.3%
Celanese Corporation logo
Celanese CorporationCE
$0
Corvex
 logo
Corvex MOVE
$899K+12.4%
RFL
Rafael Holdings, Inc.RFL
$22K-51.1%
Comstock Inc. logo
Comstock Inc.LODE
$0-100%

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+178%
P/S174×+90.2×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s other research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s other research and development expense?
Rafael Holdings, Inc. (RFL) reported other research and development expense of $22K in Q1 2026.
How has Rafael Holdings, Inc.'s other research and development expense changed year-over-year?
Rafael Holdings, Inc.'s other research and development expense decreased by 51.1% year-over-year, from $45K to $22K.
What is the long-term trend for Rafael Holdings, Inc.'s other research and development expense?
Over 4 years (2021 to 2025), Rafael Holdings, Inc.'s other research and development expense has grown at a -25.1% compound annual growth rate (CAGR), from $523K to $165K.
What does other research and development expense mean?
Research and development costs that are not directly attributable to primary clinical trials or core product development projects. This includes ancillary scientific support, overhead, or secondary exploratory research activities.